INTRODUCTION: There is converging evidence supporting hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in schizophrenia spectrum disorders (SSD), such as schizotypal personality disorder (SPD), first-episode schizophrenia (FESZ) and chronic schizophrenia (CHSZ). Such an aberrant HPA activity might have volumetric consequences on the pituitary gland. However, previous magnetic resonance imaging (MRI) studies assessing pituitary volume (PV) in SSD are conflicting. The main objective of this study was to examine further PV in SSD. METHODS: PV were manually traced on structural MRIs in 137 subjects, including subjects with SPD (n = 40), FESZ (n = 15), CHSZ (n = 15), and HC (n = 67). We used an ANCOVA to test PV between groups and gender while controlling for inter-subject variability in age, years of education, socioeconomic status, and whole brain volume. RESULTS: Overall, women had larger PV than men, and within the male sample all SSD subjects had smaller PV than HC, statistically significant only for the SPD group. In addition, dose of medication, illness duration and age of onset were not associated with PV. CONCLUSION: Chronic untreated HPA hyperactivity might account for smaller PV in SPD subjects, whereas the absence of PV changes in FESZ and CHSZ patients might be related to the normalizing effects of antipsychotics on PV. SPD studies offer a way to examine HPA related alterations in SSD without the potential confounds of medication effects. Published by Elsevier B.V.
INTRODUCTION: There is converging evidence supporting hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in schizophrenia spectrum disorders (SSD), such as schizotypal personality disorder (SPD), first-episode schizophrenia (FESZ) and chronic schizophrenia (CHSZ). Such an aberrant HPA activity might have volumetric consequences on the pituitary gland. However, previous magnetic resonance imaging (MRI) studies assessing pituitary volume (PV) in SSD are conflicting. The main objective of this study was to examine further PV in SSD. METHODS:PV were manually traced on structural MRIs in 137 subjects, including subjects with SPD (n = 40), FESZ (n = 15), CHSZ (n = 15), and HC (n = 67). We used an ANCOVA to test PV between groups and gender while controlling for inter-subject variability in age, years of education, socioeconomic status, and whole brain volume. RESULTS: Overall, women had larger PV than men, and within the male sample all SSD subjects had smaller PV than HC, statistically significant only for the SPD group. In addition, dose of medication, illness duration and age of onset were not associated with PV. CONCLUSION:Chronic untreated HPA hyperactivity might account for smaller PV in SPD subjects, whereas the absence of PV changes in FESZ and CHSZ patients might be related to the normalizing effects of antipsychotics on PV. SPD studies offer a way to examine HPA related alterations in SSD without the potential confounds of medication effects. Published by Elsevier B.V.
Authors: C C Dickey; M E Shenton; Y Hirayasu; I Fischer; M M Voglmaier; M A Niznikiewicz; L J Seidman; S Fraone; R W McCarley Journal: Am J Psychiatry Date: 2000-01 Impact factor: 18.112
Authors: Y Hirayasu; S Tanaka; M E Shenton; D F Salisbury; M A DeSantis; J J Levitt; C Wible; D Yurgelun-Todd; R Kikinis; F A Jolesz; R W McCarley Journal: Cereb Cortex Date: 2001-04 Impact factor: 5.357
Authors: R B Sassi; M Nicoletti; P Brambilla; K Harenski; A G Mallinger; E Frank; D J Kupfer; M S Keshavan; J C Soares Journal: Biol Psychiatry Date: 2001-08-15 Impact factor: 13.382
Authors: Y Hirayasu; R W McCarley; D F Salisbury; S Tanaka; J S Kwon; M Frumin; D Snyderman; D Yurgelun-Todd; R Kikinis; F A Jolesz; M E Shenton Journal: Arch Gen Psychiatry Date: 2000-07
Authors: Chang Uk Lee; Martha E Shenton; Dean F Salisbury; Kiyoto Kasai; Toshiaki Onitsuka; Chandlee C Dickey; Deborah Yurgelun-Todd; Ron Kikinis; Ferenc A Jolesz; Robert W McCarley Journal: Arch Gen Psychiatry Date: 2002-09